Natural plant extract for treating chronic obstructive pulmonary disease as well as preparation method and application thereof

Abstract

The invention provides a natural plant extract for treating chronic obstructive pulmonary disease as well as a preparation method and application thereof, and relates to the technical field of medicines. The natural plant extract comprises the following raw materials in parts by weight: 6-10 parts of a cynanchum chinense extract, 5-7 parts of a polygonum palmatum extract, 4-6 parts of an ailanthus altissima extract, 1-3 parts of an elsholtzia calyx extract and 1-3 parts of a streptocaulon griffithii extract. The natural plant extract disclosed by the invention can reduce expression levels of inflammatory factors TNF-alpha, IL-1beta and IL-17A of the chronic obstructive pulmonary disease, can reduce pause time at the end period of expiration of the lung, 50% expiration flow rate and airway stenosis index, can improve the maximum expiration volume of the lung, and can improve the lung function of a model mouse with the chronic obstructive pulmonary disease; a new natural medicine is provided for treating the chronic obstructive pulmonary disease, and the medicine is remarkable in curative effect, safe, non-toxic, free of side effects and good in application prospect.

Description

TECHNICAL FIELD

[0001] The present application relates to the technical field of medicine, in particular to a natural plant extract for treating chronic obstructive pulmonary disease and a preparation method and application thereof. BACKGROUND

[0002] Chronic obstructive pulmonary disease is the most common chronic respiratory disease, which, together with cardiovascular disease, diabetes and tumor, constitutes the four major chronic diseases in the world, with a global prevalence rate of 9-10%. It has become the third leading cause of death in the world. Chronic obstructive pulmonary disease is characterized by persistent low-grade lung inflammation and airflow obstruction. In recent years, air pollution has been serious, and workers are exposed to toxic gases or smoke in the workplace. It is estimated that the incidence and mortality of chronic obstructive pulmonary disease will continue to rise in the coming decades.

[0003] The current treatment of chronic obstructive pulmonary disease includes avoiding exposure to risk factors, drug treatment, surgery, and other treatments. The most important treatment is drug treatment, including drugs for promoting bronchial relaxation, antibiotics and hormone drugs. Since chronic obstructive pulmonary disease is a complex disease caused by multiple factors, any single active ingredient drug cannot reverse the progression of chronic obstructive pulmonary disease, resulting in less than ideal treatment effect of existing drugs. In addition, western medicine has greater side effects, and long-term use of antibiotics, hormones and other drugs can cause immunosuppression and immune tolerance and other side effects.

[0004] Therefore, it is of practical significance to develop a drug with good treatment effect on chronic obstructive pulmonary disease and no natural toxic side effects. SUMMARY

[0005] In view of this, the present application provides a natural plant extract for treating chronic obstructive pulmonary disease and a preparation method and application thereof.

[0006] The technical solution of the present application is as follows: The present application provides a natural plant extract for treating chronic obstructive pulmonary disease, which comprises the following raw materials in parts by weight: 6-10 parts of Cynanchum thesioides extract, 5-7 parts of Polygonum capitatum extract, 4-6 parts of Commelina communis extract, 1-3 parts of Elsholtzia rugulosa extract and 1-3 parts of Spermacoce latifolia extract.

[0007] Further, the preparation method of the Cynanchum thesioides extract is as follows: Cynanchum thesioides is crushed and mixed with an ethanol solution, ultrasonic extraction, filtration, and vacuum concentration to obtain Cynanchum thesioides extract; The feed liquid ratio of the Radix Taxilli and the ethanol solution is 1:6-8 g / mL; the concentration of the ethanol solution is 40%-60% v / v; the frequency of the ultrasonic extraction is 20-30 kHz, the temperature is 40-60 ℃, and the time is 2-4 h.

[0008] Further, the preparation method of the extract of Polygonum capitatum is: The Polygonum capitatum is crushed, mixed with an ethanol solution, and enzymatically hydrolyzed with a compound enzyme, centrifuged, and concentrated under reduced pressure to obtain the extract of Polygonum capitatum; The feed liquid ratio of the Polygonum capitatum and the ethanol solution is 1:5-7 g / mL; the concentration of the ethanol solution is 50%-70% v / v; the addition amount of the compound enzyme is 1%-3% of the weight of the Polygonum capitatum; the compound enzyme is composed of cellulase, hemicellulase, and β-glucanase in a mass ratio of 1:0.8-1:0.5-0.7; the enzymatic hydrolysis temperature is 30-35 ℃, and the time is 1-2 h.

[0009] Further, the preparation method of the extract of Commelina communis is: The Commelina communis is placed in a supercritical CO2 extraction device for extraction, and the extract liquid is concentrated under reduced pressure to obtain the extract of Commelina communis; The supercritical CO2 extraction is first static extraction under the conditions of a pressure of 20-30 MPa and a temperature of 60-70 ℃ for 30-40 min, and then dynamic extraction at 2 L / min for 20-30 min.

[0010] Further, the preparation method of the extract of Elsholtzia blanda is: The Elsholtzia blanda is mixed with deionized water, distilled under reduced pressure, and the distillate is collected and concentrated to a solid content of 5-7 mg / mL to obtain the extract of Elsholtzia blanda; The feed liquid ratio of the Elsholtzia blanda and the deionized water is 1:10-15 g / mL; the distillation under reduced pressure is carried out at 80-85 ℃ and -0.08~-0.09 MPa for 1-2 h.

[0011] Further, the preparation method of the extract of Speranskia balansae is: The Speranskia balansae is crushed, mixed with a citric acid solution, and fermented by adding a strain, and the fermentation liquid is concentrated and vacuum dried to obtain the extract of Speranskia balansae; The feed liquid ratio of the Speranskia balansae and the citric acid solution is 1:3-5 g / mL; the concentration of the citric acid is 3-5 wt%; the addition amount of the strain is 0.2%-0.4% of the weight of the Speranskia balansae; the strain is composed of Lactobacillus plantarum and Lactobacillus rhamnosus in a mass ratio of 1:1-3; the fermentation is carried out at 30-35 ℃ for 12-15 h.

[0012] The application further provides a preparation method of the natural plant extract for treating chronic obstructive pulmonary disease, and the preparation method comprises the following steps: mixing extracts of Cynanchum thesioides H.S. Lo, Polygonum capitatum Buch.-Ham., Monochoria vaginalis, Elsholtzia cristata and Geniostoma rupestre into each other to obtain the natural plant extract.

[0013] The application further provides application of the natural plant extract in preparation of a medicine for resisting chronic obstructive pulmonary disease.

[0014] Further, the concentration of the natural plant extract in the medicine is 5-10 wt%.

[0015] Further, the natural plant extract can reduce expression levels of inflammatory factors of chronic obstructive pulmonary disease, including TNF-α, IL-1β and IL-17A. The natural plant extract can reduce end-expiratory pause time, 50% expiratory flow rate and airway narrowing index of the lung, and improve maximum expiratory capacity of the lung.

[0016] Compared with the prior art, the application has the following beneficial effects: The application provides a natural plant extract composed of extracts of Cynanchum thesioides H.S. Lo, Polygonum capitatum Buch.-Ham., Monochoria vaginalis, Elsholtzia cristata and Geniostoma rupestre, and the steroidal, flavonoid and terpenoid components of the extract of Cynanchum thesioides H.S. Lo can block a signal path and reduce release of proinflammatory factors; the extract of Polygonum capitatum Buch.-Ham. is rich in polyphenols and flavonoid compounds, and has antioxidant and anti-inflammatory effects; the phenolic acid and triterpenoid components of the extract of Monochoria vaginalis, the volatile oil component of the extract of Elsholtzia cristata and the alkaloids of the extract of Geniostoma rupestre synergistically act, and the natural plant extract has good efficacy in preparation of a medicine for resisting chronic obstructive pulmonary disease. Specifically, the natural plant extract can reduce expression levels of inflammatory factors TNF-α, IL-1β and IL-17A of chronic obstructive pulmonary disease, can reduce end-expiratory pause time, 50% expiratory flow rate and airway narrowing index of the lung, can improve maximum expiratory capacity of the lung, and can improve lung function of a chronic obstructive pulmonary disease model mouse; the natural plant extract provides a new natural medicine for treating chronic obstructive pulmonary disease, has remarkable curative effect, is safe and non-toxic, and has no side effects. DETAILED DESCRIPTION

[0017] In order to better understand the technical content of the application, the following specific embodiments are provided to further illustrate the application.

[0018] The experimental methods used in the embodiments of the application are all conventional methods if no special instructions are given.

[0019] The materials and reagents used in the embodiments of the application can be obtained from commercial channels if no special instructions are given.

[0020] The preparation method of the extract of Rubus crataegifolius Bge. in the application is as follows: Rubus crataegifolius Bge. is crushed, mixed with 60% v / v ethanol solution according to the solid-liquid ratio of 1:6 g / mL, ultrasonically extracted at 30 kHz and 60 DEG C for 24 h, filtered, and concentrated under reduced pressure to obtain the extract of Rubus crataegifolius Bge.

[0021] The preparation method of the extract of Polygonum divaricatum Buch.-Ham. in the application is as follows: Polygonum divaricatum Buch.-Ham. is crushed, mixed with 50% v / v ethanol solution according to the solid-liquid ratio of 1:5 g / mL, and composite enzyme is added, the amount of the composite enzyme being 1% of the mass of Polygonum divaricatum Buch.-Ham., the composite enzyme being composed of cellulase, hemicellulase and beta-glucanase at a mass ratio of 1:0.8:0.5, enzymolysis is carried out at 30-35 DEG C for 1 h, centrifugation is carried out, and concentration is carried out under reduced pressure to obtain the extract of Polygonum divaricatum Buch.-Ham.

[0022] The preparation method of the extract of Aneilema keisak (Sieb. et Zucc.) Kunth in the application is as follows: Aneilema keisak (Sieb. et Zucc.) Kunth is placed in a supercritical CO2 extraction device, static extraction is carried out at a pressure of 30 MPa and a temperature of 70 DEG C for 30 min, and then dynamic extraction is carried out at 2 L / min for 20 min, the extract liquid is concentrated under reduced pressure to obtain the extract of Aneilema keisak (Sieb. et Zucc.) Kunth.

[0023] The preparation method of the extract of Elsholtzia blanda Benth. in the application is as follows: Elsholtzia blanda Benth. is mixed with deionized water according to the solid-liquid ratio of 1:10 g / mL, distillation is carried out under reduced pressure at 80 DEG C and -0.08 MPa for 1 h, the distillate is collected, and the distillate is concentrated to a solid content of 5 mg / mL to obtain the extract of Elsholtzia blanda Benth.

[0024] The preparation method of the extract of Millettia pinnata (L.) Panzer in the application is as follows: Millettia pinnata (L.) Panzer is crushed, mixed with 3 wt% citric acid solution according to the solid-liquid ratio of 1:5 g / mL, and 0.2% of the mass of Millettia pinnata (L.) Panzer of a strain is added, the strain being composed of Lactobacillus plantarum and Lactobacillus rhamnosus at a mass ratio of 1:1, fermentation is carried out at 30 DEG C for 125 h, the fermentation liquid is concentrated, and vacuum drying is carried out to obtain the extract of Millettia pinnata (L.) Panzer.

[0025] The preparation method of the natural plant extract in the application comprises the following steps: the extract of Rubus crataegifolius Bge., the extract of Polygonum divaricatum Buch.-Ham., the extract of Aneilema keisak (Sieb. et Zucc.) Kunth, the extract of Elsholtzia blanda Benth. and the extract of Millettia pinnata (L.) Panzer are mixed to obtain the natural plant extract.

[0026] The concentration of the natural plant extract in the anti-chronic obstructive pulmonary disease drug in the application is 5 wt%.

[0027] Example 1 The natural plant extract in the example comprises the following raw materials according to weight parts: 8 parts of the extract of Rubus crataegifolius Bge., 6 parts of the extract of Polygonum divaricatum Buch.-Ham., 5 parts of the extract of Aneilema keisak (Sieb. et Zucc.) Kunth, 2 parts of the extract of Elsholtzia blanda Benth. and 2 parts of the extract of Millettia pinnata (L.) Panzer.

[0028] Example 2 The natural plant extract of this example includes the following raw materials in parts by weight: 6 parts of C. acutangula extract, 5 parts of P. chinensis extract, 4 parts of A. indicum extract, 1 part of E. japonicum extract, and 1 part of S. japonica extract.

[0029] Example 3 The natural plant extract of this example includes the following raw materials in parts by weight: 10 parts of C. acutangula extract, 7 parts of P. chinensis extract, 6 parts of A. indicum extract, 3 parts of E. japonicum extract, and 3 parts of S. japonica extract.

[0030] Comparative Example 1 The difference from Example 1 is that C. acutangula extract is absent, and the amount of the absent substance is distributed in the ratio of P. chinensis extract, A. indicum extract, E. japonicum extract, and S. japonica extract, and the other parts are consistent with Example 1.

[0031] Comparative Example 2 The difference from Example 1 is that P. chinensis extract is absent, and the amount of the absent substance is distributed in the ratio of C. acutangula extract, A. indicum extract, E. japonicum extract, and S. japonica extract, and the other parts are consistent with Example 1.

[0032] Comparative Example 3 The difference from Example 1 is that A. indicum extract is absent, and the amount of the absent substance is distributed in the ratio of C. acutangula extract, P. chinensis extract, E. japonicum extract, and S. japonica extract, and the other parts are consistent with Example 1.

[0033] Comparative Example 4 The difference from Example 1 is that E. japonicum extract is absent, and the amount of the absent substance is distributed in the ratio of C. acutangula extract, P. chinensis extract, A. indicum extract, and S. japonica extract, and the other parts are consistent with Example 1.

[0034] Comparative Example 5 The difference from Example 1 is that S. japonica extract is absent, and the amount of the absent substance is distributed in the ratio of C. acutangula extract, P. chinensis extract, A. indicum extract, and E. japonicum extract, and the other parts are consistent with Example 1.

[0035] Comparative Example 6 The difference from Example 1 is that all the extracts are extracted by the ordinary alcohol extraction method, and the other parts are consistent with Example 1.

[0036] Test Example Experimental method: 110 male C57BL / 6 mice aged 6-8 weeks and weighing 20g±2g were purchased. The mice were randomly divided into a blank control group (10 mice) and a modeling group (100 mice). The mice in the modeling group were exposed to cigarette smoke (10 cigarettes for 20 min each time, twice a day), and intranasal instillation of lipopolysaccharide (10 μg per mouse) was performed every 15 days. The mice were exposed to cigarette smoke for 100 days to establish a mouse model of chronic obstructive pulmonary disease. The blank control group was instilled with the same dose of PBS.

[0037] The mice in the modeling group were divided into a model group and Example 1-3 groups and Comparative Example 1-6 groups, 10 mice in each group. From the 60th day, the mice in the Example 1-3 groups and the Comparative Example 1-6 groups were intervened with the corresponding natural plant extracts, once a day, and the mice were given the natural plant extracts by gavage, and the dose was 20 mg / kg. The mice in the model group and the blank control group were given the same dose of PBS.

[0038] 1. After the mice were anesthetized, the trachea was exposed, and a cut was made in the throat of the mouse with surgical scissors. A breathing adapter was quickly inserted into the trachea, and then connected to a lung function detector. After the mouse's breathing stabilized, the changes in the lung function-related parameters (50% expiratory flow rate, expiratory end pause, maximum expiratory volume, and airway stenosis index) were determined and recorded. The results are shown in Table 1.

[0039] Table 1

[0040] Note: a Compared with the blank control group, P<0.05, b Compared with the model group, P<0.05.

[0041] As can be seen from Table 1, the natural plant extracts prepared in Examples 1-3 can improve the lung function of the mouse model of chronic obstructive pulmonary disease, specifically: can reduce the expiratory end pause time, 50% expiratory flow rate and airway stenosis index, and at the same time increase the maximum expiratory volume of the lung; Comparative Examples 1-5 lack any extract, and the effect is decreased, indicating that the natural plant extracts of the present application are indispensable.

[0042] 2. After the lung function detection was completed, the mouse was lavaged to obtain the bronchoalveolar lavage fluid. A sterilized 20G PE needle was inserted into the exposed trachea, and the PE needle was fixed with surgical thread. 0.8 mL of pre-cooled PBS on ice was taken with a 1 mL sterile syringe, and the PE needle was connected to the mouse lung for lavage. The mouse was lavaged gently for three times, and the bronchoalveolar lavage fluid was obtained. The bronchoalveolar lavage fluid was centrifuged at 5000g and 4℃ for 10 min, and the supernatant was taken. The content of TNF-α, IL-1β and IL-17A was determined by ELISA kit. The results are shown in Table 2.

[0043] Table 2

[0044] Note: c compared with the blank control group, P<0.05, d compared with the model group, P<0.05.

[0045] As can be seen from Table 2, compared with the blank control group, the expression levels of inflammatory factors (TNF-α, IL-1β and IL-17A) of the model group were significantly increased (P<0.05), indicating that the model group of mice was successfully modeled. Compared with the model group, the expression levels of inflammatory factors TNF-α, IL-1β and IL-17A of the mice after intervention of the natural plant extracts of Examples 1-3 were significantly reduced (P<0.05), indicating that the natural plant extracts prepared by the present application can reduce the expression levels of inflammatory factors TNF-α, IL-1β and IL-17A of chronic obstructive pulmonary disease, and reduce the inflammation. Comparative Examples 1-5 lack any extract, and the effect is reduced, indicating that the natural plant extracts of the present application are indispensable.

[0046] The above description is merely preferred embodiments of the present application but not to confine the present application. Any modification, equivalent replacement, improvement, etc. made within the spirit and principle of the present application shall be included in the protection scope of the present application.

Claims

1. A natural plant extract for treating chronic obstructive pulmonary disease, characterized in that: The invention comprises the following raw materials in parts by weight: 6-10 parts of anemone vine extract, 5-7 parts of Polygonum multiflorum extract, 4-6 parts of water hyacinth extract, 1-3 parts of Elsholtzia calyx extract and 1-3 parts of Rhizoma Cibotii extract.

2. The natural plant extract for treating chronic obstructive pulmonary disease according to claim 1, wherein The preparation method of the anser vine extract is as follows: The anemone vine is crushed, mixed with an ethanol solution, subjected to ultrasonic extraction, filtered, and concentrated under reduced pressure to obtain an anemone vine extract; The material-liquid ratio of the anemone vine to the ethanol solution is 1:6-8 g / mL; the concentration of the ethanol solution is 40%-60% v / v; the frequency of the ultrasonic extraction is 20-30 kHz, the temperature is 40-60° C., and the time is 2-4 hours.

3. The natural plant extract for treating chronic obstructive pulmonary disease according to claim 1, wherein The preparation method of the Polygonum multiflorum extract is as follows: The Polygonum multiflorum extract was obtained by grinding the Polygonum multiflorum, mixing the mixture with an ethanol solution, adding a composite enzyme for enzymolysis, centrifuging, and concentrating under reduced pressure. The material-liquid ratio of the polygonum multiflorum and the ethanol solution is 1:5-7 g / mL; the concentration of the ethanol solution is 50%-70% v / v; the added amount of the complex enzyme is 1%-3% of the weight of the polygonum multiflorum; the complex enzyme is composed of cellulase, hemicellulase and β-glucanase in a mass ratio of 1:0.8-1:0.5-0.7; the enzymatic hydrolysis temperature is 30-35°C, and the time is 1-2 hours.

4. The natural plant extract for treating chronic obstructive pulmonary disease according to claim 1, wherein The preparation method of the water hyacinth extract is as follows: placing the water hyacinthus in a supercritical CO2 extraction device for extraction, and concentrating the extract under reduced pressure to obtain the water hyacinthus extract; The supercritical CO2 extraction is first performed at a pressure of 20-30 MPa and a temperature of 60-70°C for 30-40 minutes under static extraction, followed by dynamic extraction at 2 L / min for 20-30 minutes.

5. The natural plant extract for treating chronic obstructive pulmonary disease according to claim 1, wherein The preparation method of the Elsholtzia calyx extract is as follows: The Elsholtzia calycifolia extract was obtained by mixing the Elsholtzia calycifolia extract with deionized water, performing distillation under reduced pressure, collecting the distillate, and concentrating the distillate to a solid content of 5-7 mg / mL. The material-liquid ratio of the Elsholtzia calyx and deionized water is 1:10-15 g / mL; and the reduced pressure distillation is carried out at 80-85° C. and -0.08-0.09 MPa for 1-2 hours.

6. The natural plant extract for treating chronic obstructive pulmonary disease according to claim 1, wherein The preparation method of the Rhizoma Coptidis extract is as follows: The ginseng root is crushed, mixed with a citric acid solution, and the bacteria are added for fermentation. The fermentation liquid is concentrated and vacuum dried to obtain the ginseng root extract; The material-liquid ratio of the ancient sheep vine and the citric acid solution is 1:3-5g / mL; the concentration of the citric acid is 3-5wt%; the amount of the added strain is 0.2%-0.4% of the weight of the ancient sheep vine; the strain is composed of Lactobacillus plantarum and Lactobacillus rhamnosus in a mass ratio of 1:1-3; the fermentation is carried out at 30-35°C for 12-15h.

7. The method for preparing a natural plant extract for treating chronic obstructive pulmonary disease according to claim 1, wherein: The preparation method comprises the following steps: mixing anemone vine extract, polygonum multiflorum extract, water hyacinth extract, esculenta calyx extract and iris vine extract to obtain a natural plant extract.

8. Use of the natural plant extract for treating chronic obstructive pulmonary disease according to any one of claims 1 to 6 in the preparation of a medicament for treating chronic obstructive pulmonary disease.

9. The use according to claim 8, characterized in that The concentration of the natural plant extract in the medicine is 5-10 wt %.

10. The use according to claim 8, characterized in that The natural plant extract can reduce the expression levels of inflammatory factors in chronic obstructive pulmonary disease, including TNF-α, IL-1β and IL-17A; The natural plant extract can reduce the lung end-expiratory pause time, 50% expiratory flow rate and airway stenosis index, and increase the maximum expiratory volume of the lung.

Images